Clinical Trial Update: A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan [Phase 3]

View source ↗

Summary

Phase 3 open-label study evaluating [68Ga]Ga-DOTA-TATE PET imaging in patients with neuroendocrine neoplasms (and healthy volunteers) in Japan; the trial is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasm
• Neuroendocrine Tumor

Drugs mentioned

• [68Ga]Ga-DOTA-TATE (gallium-68 DOTATATE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neuroendocrine Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2026-02-03